L-DOPA induced-endogenous 6-hydroxydopamine is the cause of aggravated dopaminergic neurodegeneration in Parkinson's disease patients

Medical Hypotheses

Volumn 79, Issue 2, 2012, Pages 271-273

  Borah, Anupom ^a   Mohanakumar, Kochupurackal P ^b  

^a ASSAM UNIVERSITY   (India)

^b INDIAN INSTITUTE OF CHEMICAL BIOLOGY   (India)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; DOPAMINE; LEVODOPA; MELATONIN; OXIDOPAMINE; SALICYLIC ACID;

ARTICLE; DISORDERS OF MITOCHONDRIAL FUNCTIONS; DOPAMINERGIC NERVE CELL; DRUG EFFECT; HUMAN; LEWY BODY; NERVE DEGENERATION; OXIDATIVE STRESS; PARKINSON DISEASE; PATHOPHYSIOLOGY;

ANIMALS; BRAIN; DOPAMINERGIC NEURONS; HUMANS; LEVODOPA; MODELS, NEUROLOGICAL; NEURODEGENERATIVE DISEASES; OXIDOPAMINE; PARKINSONIAN DISORDERS;

EID: 84863329538     PISSN: 03069877     EISSN: 15322777     Source Type: Journal    
DOI: 10.1016/j.mehy.2012.05.008     Document Type: Article

References (40)

1. Carlsson A. Treatment of Parkinson's with L-DOPA. The early discovery phase, and a comment on current problems. J Neural Transm 2002, 109:777-787.
2. Hornykiewicz O. Biochemical aspects of Parkinson's disease. Neurology 1998, 51:S2-S9.
3. Lewitt P.A. Levodopa for the treatment of Parkinson's disease. N Engl J Med 2008, 359:2468-2476.
4. Hui J.S., Murdock G.A., Chung J.S., Lew M.F. Behavioral changes as side effects of medication treatment for Parkinson's disease. Adv Neurol 2005, 96:114-129.
5. Muller T. Motor complications, levodopa metabolism and progression of Parkinson's disease. Expert Opin Drug Metab Toxicol 2011, 7:847-855.
6. Fahn S., Oakes D., Shoulson I., Kieburtz K., Rudolph A., Lang A., et al. Parkinson study group. Levodopa and the progression of Parkinson's disease. N Engl J Med 2004, 9:2498-2508.
7. Borah A., Mohanakumar K.P. Long-term L-DOPA treatment causes indiscriminate increase in dopamine levels at the cost of serotonin synthesis in discrete brain regions of rats. Cell Mol Neurobiol 2007, 27:985-996.
8. Cenci M.A., Lindgren H.S. Advances in understanding L-DOPA-induced dyskinesia. Curr Opin Neurobiol 2007, 17:665-671.
9. Calabresi P., Di Filippo M., Ghiglieri V., Tambasco N., Picconi B. Levodopa-induced dyskinesias in patients with Parkinson's disease: filling the bench-to-bedside gap. Lancet Neurol 2010, 9:1106-1117.
10. Graham D.G. Oxidative pathways for catecholamines in the genesis of neuromelanin and cytotoxic quinones. Mol Pharmacol 1978, 14:633-643.
11. Napolitano A., Pezzella A., Prota G. New reaction pathways of dopamine under oxidative stress conditions: nonenzymatic iron-assisted conversion to norepinephrine and the neurotoxins 6-hydroxydopamine and 6,7-dihydroxytetrahydroisoquinoline. Chem Res Toxicol 1999, 12:1090-1097.
12. Hattoria N., Wanga M., Taka H., Fujimura T., Yoritaka A., Kubo S., et al. Toxic effects of dopamine metabolism in Parkinson's disease. Parkinsonism Relat Disord 2009, 15:S35-s38.
13. Borah A., Mohanakumar K.P. Melatonin inhibits 6-hydroxydopamine production in the brain to protect against experimental parkinsonism in rodents. J Pineal Res 2009, 47; 293-300.
14. Borah A., Mohanakumar K.P. Salicylic acid protects against chronic L-DOPA-induced 6-OHDA generation in experimental model of parkinsonism. Brain Res 2010, 16:192-199.
15. Borah A., Mohanakumar K.P. L-DOPA-induced 6-hydroxydopamine production in the striata of rodents is sensitive to the degree of denervation. Neurochem Int 2010, 56:352-362.
16. Ungerstedt U., Arbuthnott G.W. Quantitative recording of rotational behaviour in rats after 6-hydroxydopamine lesions of the nigrostriatal dopamine system. Brain Res 1970, 24:485-493.
17. Beal M.F. Experimental models of Parkinson's disease. Nat Rev Neurosci 2001, 2:325-332.
18. Grealish S., Mattsson B., Draxler P., Björklund A. Characterisation of behavioural and neurodegenerative changes induced by intranigral 6-hydroxydopamine lesions in a mouse model of Parkinson's disease. Eur J Neurosci 2010, 31:2266-2278.
19. Blum D., Torch S., Lambeng N., Nissou M., Benabid A.L., Sadoul R., et al. Molecular pathways involved in the neurotoxicity of 6-OHDA, dopamine and MPTP: contribution to the apoptotic theory in Parkinson's disease. Prog Neurobiol 2001, 65:135-172.
20. Hastings T.G. Enzymatic oxidation of dopamine: the role of prostaglandin H synthase. J Neurochem 1995, 64:919-924.
21. Hastings T.G., Lewis D.A., Zigmond M.J. Role of oxidation in the neurotoxic effects of intrastriatal dopamine injections. Proc Natl Acad Sci USA 1996, 93:1956-1961.
22. Glinka Y., Gassen M., Youdim M.B. Mechanism of 6-hydroxydopamine neurotoxicity. J Neural Transm 1997, 50(Suppl.):55-66.
23. Jonsson G., Sachs C. Effects of 6-hydroxydopamine on the uptake and storage of noradrenaline in sympathetic adrenergic neurons. Eur J Pharmacol 1970, 9:141-155.
24. Slivka A., Cohen G. Hydroxyl radical attack on dopamine. J Biol Chem 1985, 260:15466-15472.
25. Maharaj H., Sukhdev Maharaj D., Scheepers M., Mokokong R., Daya S. L-DOPA administration enhances 6-hydroxydopamine generation. Brain Res 2005, 1063:180-186.
26. Borah A., Mohanakumar K.P. Long term L-DOPA treatment causes production of 6 OHDA in the mouse striatum: involvement of hydroxyl radical. Ann Neurosci 2009, 16:160-165.
27. Seiden L.S., Vosmer G. Formation of 6-hydroxydopamine in caudate nucleus of the rat brain after a single large dose of methyl amphetamine. Pharmacol Biochem Behav 1984, 21:29-31.
28. Liao P.-C., Kuo Y.-M., Chang Y.-C., Lin C., Cherng C.-F.G., Yu L. Striatal formation of 6-hydroxydopamine in mice treated with pargyline, pyrogallol and methamphetamine. J Neural Transm 2003, 110:487-494.
29. Andrew R., Watson D.G., Best S.A., Midgley J.M., Wenlong H., Petty R.K. The determination of hydroxydopamines and other trace amines in the urine of parkinsonian patients and normal controls. Neurochem Res 1993, 18:1175-1177.
30. Curtius H.C., Wolfensberger M., Steinmann B., Redweik U., Siegfried J. Mass fragmentography of dopamine and 6-hydroxydopamine. Application to the determination of dopamine in human brain biopsies from the caudate nucleus. J Chromatogr 1974, 99:529-540.
31. Hashimoto M., Takeda A., Hsu L.J., Takenouchi T., Masliah E. Role of cytochrome c as a stimulator of alpha-synuclein aggregation in Lewy body disease. J Biol Chem 1999, 274:28849-28852.
32. Souza J.M., Giasson B.I., Chen Q., Lee V.M., Ischiropoulos H. Dityrosine cross-linking promotes formation of stable alpha-synuclein polymers. Implication of nitrative and oxidative stress in the pathogenesis of neurodegenerative synucleinopathies. J Biol Chem 2000, 275:18344-18349.
33. Giasson B.I., Ischiropoulos H., Lee V.M., Trojanowski J.Q. The relationship between oxidative/nitrative stress and pathological inclusions in Alzheimer's and Parkinson's diseases. Free Radic Biol Med 2002, 32:1264-1275.
34. Keeney P.M., Xie J., Capaldi R.A., Bennett J.P. Parkinson's disease brain mitochondrial complex I has oxidatively damaged subunits and is functionally impaired and misassembled. J Neurosci 2006, 26:5256-5264.
35. Betarbet R., Sherer T.B., MacKenzie G., Garcia-Osuna M., Panov A.V., Greenamyre J.T. Chronic systemic pesticide exposure reproduces features of Parkinson's disease. Nat Neurosci 2000, 3:1301-1306.
36. Feng Y., Liang Z.H., Wang T., Qiao X., Liu H.J., Sun S.G. Alpha-synuclein redistributed and aggregated in rotenone-induced Parkinson's disease rats. Neurosci Bull 2006, 22:288-293.
37. Gallardo G., Schlüter O.M., Südhof T.C. A molecular pathway of neurodegeneration linking alpha-synuclein to ApoE and Abeta peptides. Nat Neurosci 2008, 11:301-308.
38. Goldberg M.S., Lansbury P.T., Helfand S.L. Is there a cause-and-effect relationship between alpha-synuclein fibrillization and Parkinson's disease?. Nat Cell Biol 2000, 2:E115-E119.
39. Conway K.A., Rochet J.C., Bieganski R.M., Lansbury P.T. Kinetic stabilization of the α-synuclein protofibril by a dopaminea-synuclein adduct. Science 2001, 294:1346-1349.
40. Kuhn D.M., Arthur R.E., Thomas D.M., Elferink L.A. Tyrosine hydroxylase is inactivated by catechol-quinones and converted to a redox-cycling quinoprotein: possible relevance to Parkinson's disease. J Neurochem 1999, 73:1309-1317.